Business
Final results for the year ended 31 December 2025
Cizzle Biotechnology Holdings plc has published its Annual Report and Financial Statements for the year ended 31 December 2025, detailing its progress as a UK-based diagnostics developer of early cancer tests. The report is available via a provided link and will be accessible on the National Storage Mechanism and the Company's website. The company is focused on its CIZ1B biomarker, a non-invasive blood test for early lung cancer detection, and has entered into commercial royalty-bearing arrangements and collaborations. Disclaimer*
About this update from Cizzle Biotechnology Holdings Plc
[{"type":"text","content":"\n\n30 April 2026\nCizzle Biotechnology Holdings plc\n(\"Cizzle\", \"Cizzle Biotechnology\", or the \"Company\")\nFinal results for the year ended 31 December 2025\nCizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2025 (the \"Annual Report\").\nThe Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/4787C_1-2026-4-29.pdf and will shortly be available to view on the on the National Storage Mechanism (NSM) and the Company's website: https://cizzlebiotechnology.com\nEnquiries:\n \n\n\n\n\nCizzle Biotechnology Holdings plc\n\n\nVia IFC Advisory\n\n\n\n\nAllan Syms (Executive Chairman)\n\n\n\n\n\n\n\n \n\n\n\n\nAllenby Capital Limited\n\n\n+44(0) 20 3328 5656\n\n\n\n\nJohn Depasquale (Corporate Finance)\n\n\n\n\n\n\n\nAmrit Nahal (Sales and Corporate Broking)\n\n\n\n\n\n\n\n \n\n\n\n\nIFC Advisory Limited\n\n\n+44(0) 20 3934 6632\n\n\n\n\nTim Metcalfe\n\n\n\n\n\n\n\nFlorence Staton\n\n\n\n\n\n\n\n \nAbout Cizzle Biotechnology\n \nThe CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021. \n \nFor more information, please see https://cizzlebiotechnology.com\n \nYou can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.\n \n\n","length":5278,"tagName":"div"}]